Drug donanemab seen as turning point in dementia fight
The antibody treatment donanemab slows clinical decline by around a third, a large trial confirms.
![](https://kbin.cafe/media/cache/resolve/entry_thumb/5a/b1/5ab15a1c5ebbdb27bd2a4be0147ec46d18b0fa974b851134608e0c3362ffadaf.jpg)
The antibody treatment donanemab slows clinical decline by around a third, a large trial confirms.